| 主权项 |
1. A method of judging a risk of cancer recurrence comprising a step of:
acquiring an activity value and expression level of a first cyclin-dependent-kinase (CDK), an activity value and expression level of a second CDK, an expression level of urokinase plasminogen activator (uPA), and an expression level of plasminogen activator inhibitor 1 (PAI-1) from biological samples extracted from cancer patients; judging a risk of cancer recurrence using at least one processor based on the acquired activity value and expression level of the first CDK, the activity value and expression level of the second CDK, the expression level of uPA, and the expression level of PAI-1; and outputting instructions whether or not to perform an adjuvant therapy based on the judged risk of cancer recurrence, wherein a recurrence risk score of the cancer recurrence is a value acquired based on Equation (1):
(Recurrence risk score)=F(x)×G(y) (1) (wherein x represents a first CDK specific activity, the first CDK specific activity is expressed by a first CDK activity value/first CDK expression level; y represents a specific activity ratio, the specific activity ratio is expressed by a second CDK specific activity/first CDK specific activity, and the second CDK specific activity is expressed by a second CDK activity value/second CDK expression level), and wherein the risk of cancer recurrence is judged as low when the recurrence risk score is less than a first threshold, the expression level of uPA is less than a second threshold, and the expression level of PAI-1 is less than a third threshold in the judgment step. |
